BRPI1008930A2 - formulação moduladas pelo ph para liberação pulmonar - Google Patents

formulação moduladas pelo ph para liberação pulmonar

Info

Publication number
BRPI1008930A2
BRPI1008930A2 BRPI1008930A BRPI1008930A BRPI1008930A2 BR PI1008930 A2 BRPI1008930 A2 BR PI1008930A2 BR PI1008930 A BRPI1008930 A BR PI1008930A BR PI1008930 A BRPI1008930 A BR PI1008930A BR PI1008930 A2 BRPI1008930 A2 BR PI1008930A2
Authority
BR
Brazil
Prior art keywords
modulated
formulation
pulmonary release
pulmonary
release
Prior art date
Application number
BRPI1008930A
Other languages
English (en)
Inventor
David C Cipolla
Igor Gonda
Original Assignee
Aradigm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aradigm Corp filed Critical Aradigm Corp
Publication of BRPI1008930A2 publication Critical patent/BRPI1008930A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI1008930A 2009-02-18 2010-01-26 formulação moduladas pelo ph para liberação pulmonar BRPI1008930A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15355609P 2009-02-18 2009-02-18
PCT/US2010/022071 WO2010096242A1 (en) 2009-02-18 2010-01-26 Ph-modulated formulations for pulmonary delivery

Publications (1)

Publication Number Publication Date
BRPI1008930A2 true BRPI1008930A2 (pt) 2016-03-15

Family

ID=42560133

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008930A BRPI1008930A2 (pt) 2009-02-18 2010-01-26 formulação moduladas pelo ph para liberação pulmonar

Country Status (10)

Country Link
US (3) US20100209538A1 (pt)
EP (1) EP2398462A4 (pt)
JP (2) JP5960434B2 (pt)
CN (2) CN105362256A (pt)
AU (1) AU2010216348B2 (pt)
BR (1) BRPI1008930A2 (pt)
CA (1) CA2752296C (pt)
HK (1) HK1219047A1 (pt)
RU (1) RU2606175C2 (pt)
WO (1) WO2010096242A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104208060A (zh) * 2013-05-29 2014-12-17 天津金耀集团有限公司 一种青霉素类抗生素的吸入制剂
CN104208045A (zh) * 2013-05-29 2014-12-17 天津金耀集团有限公司 一种含有青霉素类抗生素、糖皮质激素的复方的吸入制剂
CN108926570A (zh) * 2017-05-27 2018-12-04 上海颢峰医药科技有限公司 头孢类抗生素在制备预防/治疗肺动脉高压药物中的应用
SG11202011045VA (en) 2018-05-07 2020-12-30 Pharmosa Biopharm Inc Pharmaceutical composition for controlled release of treprostinil
MX2021013842A (es) * 2019-05-14 2022-01-18 Pharmosa Biopharm Inc Composicion farmaceutica de un farmaco de acido debil y metodos de administracion.
GB202006563D0 (en) * 2020-05-04 2020-06-17 Nicoventures Trading Ltd Aerosol generation
CN113257405B (zh) * 2021-06-24 2021-09-28 北京力耘柯创医学研究院 基于传感器采集营养数据的处理系统

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004951A (en) * 1989-11-22 1999-12-21 Bernstein; Lawrence Richard Administration of gallium complexes of 3-hydroxy-4-pyrones to provide physiologically active gallium levels in a mammalian individual
DK0463126T3 (da) * 1990-01-12 2000-12-11 New York Society Fremgangsmåder til fremme af sårheling og genopretning af væv
US5175006A (en) * 1990-09-21 1992-12-29 The Ohio State University Method of treating arthritis using gallium compounds
AU2672892A (en) * 1991-09-17 1993-04-27 Alcon Laboratories, Inc. Compositions containing quinolone antibiotics and sulfonate of polystyrol
US5497763A (en) * 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US7244714B1 (en) * 1998-06-12 2007-07-17 Aradigm Corporation Methods of delivering aerosolized polynucleotides to the respiratory tract
CN1133432C (zh) * 1998-08-21 2004-01-07 千寿制药株式会社 含水液体药物组合物
ES2222294T3 (es) * 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
AU2003230600B2 (en) * 2002-03-05 2009-06-04 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
US20080261902A1 (en) * 2005-04-04 2008-10-23 Shenzhen Neptunus Pharmaceutical Co., Ltd. Pharmaceutical composition containing polydatin and its application
HUE030419T2 (en) * 2005-05-18 2017-05-29 Horizon Orphan Llc Aerosolized fluoroquinolones and their uses
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
JP2009526003A (ja) * 2006-02-10 2009-07-16 パーリ・ファルマ・ゲーエムベーハー 吸入療法用噴霧状抗生物質
US8900555B2 (en) * 2006-07-27 2014-12-02 Nektar Therapeutics Insulin derivative formulations for pulmonary delivery
CA2664919A1 (en) * 2006-08-08 2008-02-21 Board Of Regents Of The University Of Texas Multistage delivery of active agents
WO2008025560A1 (en) * 2006-09-01 2008-03-06 Pari Pharma Gmbh Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy
RU2010102865A (ru) * 2007-07-24 2011-08-27 НексБио, Инк. (US) Технология изготовления микрочастиц

Also Published As

Publication number Publication date
CN102395356A (zh) 2012-03-28
HK1219047A1 (zh) 2017-03-24
RU2011138178A (ru) 2013-03-27
JP2012518036A (ja) 2012-08-09
JP2016164183A (ja) 2016-09-08
CA2752296A1 (en) 2010-08-26
US20160331744A1 (en) 2016-11-17
CN105362256A (zh) 2016-03-02
JP6188173B2 (ja) 2017-08-30
EP2398462A1 (en) 2011-12-28
US20100209538A1 (en) 2010-08-19
AU2010216348A1 (en) 2011-09-08
CA2752296C (en) 2018-09-11
JP5960434B2 (ja) 2016-08-02
RU2606175C2 (ru) 2017-01-10
US20200297722A1 (en) 2020-09-24
WO2010096242A1 (en) 2010-08-26
AU2010216348B2 (en) 2015-01-22
EP2398462A4 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
IL290077A (en) Improved lipid formulation
HUS1900013I1 (hu) Vegyületek és készítmények mint protein kináz inhibitorok
BRPI0919447A2 (pt) derivados do ácido 1-amino-2-ciclobutiletilborônico
BR112012002335A2 (pt) pigmento composto e método para preparação do mesmo
BR112012004807A2 (pt) vacina para pcsk9
BRPI0919466A2 (pt) composição farmacêutica para liberação modificada
BRPI1014262A2 (pt) anticorpos específicos para caderina-17
ECSP12011999A (es) Derivados benzamida sustituidos
BRPI0919548A2 (pt) pacote para inserto
BRPI1009465A2 (pt) Formulação
DK2513106T3 (da) Heteroaromatiske aryltriazol-derivater som pde10a-enzyminhibitorer
DE502009000614D1 (de) Anhängekupplung
BRPI0915492A2 (pt) sistemas e métodos para transferir valores
BRPI0915176A2 (pt) acoplador
ATE534634T1 (de) 2-phenyl-4-cyclopropyl-pyrimidinderivate
BR112012028007A2 (pt) composição aquosa
BRPI0915106A2 (pt) benzimidazóis substituídos para neurofibromatose
BRPI0921065A2 (pt) vacina marcadora para salmonela
HUE042857T2 (hu) Gyors hatóanyag-leadású készítmények
BR112012011093A2 (pt) antígenos para actinobacillus suis
ES1067973Y (es) Mordedor exprime-alimentos para bebes
ES1067470Y (es) Taco expansible para paredes o similares
ES1067680Y (es) Faja para adelgazar
FI11277U1 (fi) Puuviilulevy
ES1067107Y (es) Entresuela para calzado

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL